ライフサイエンスコーパス: MVR

1 MVR and receptor saturation both occur at some high p sy

2 MVR blade treatment across 170.0 +/- 14.1 degrees of TM

3 MVR consequently represents a widespread mechanism that

4 MVR data suggest that mouse minisatellites mutate mainly

5 MVR determines the temporal and spatial dispersion of tr

6 MVR may be an appropriate strategy for children <5 years

7 MVR measurements obtained with susceptibility-weighted M

8 MVR or MV repair after previous CABG is associated with

9 MVR permits small presynaptic voltage changes to elicit

10 MVR typing could, therefore, improve the ascertainment o

11 MVR typing of rare-length alleles indicates that they ar

12 MVR typing of the common alleles a1, a2, a3, and a4 show

13 MVR via conventional sternotomy has been an established

14 MVR was initially identified at specialized synapses but

15 MVR was most advantageous in neurons with short time con

16 MVR was performed 176 times on 139 patients.

17 MVR, however, is preferred for select patients.

18 MVR-calibrated measurements of allele length yield rare

19 n additional reoperation: 4 received CABG, 2 MVR, and 2 MV repair.

20 There were 33 AVR (5.4%) and 38 MVR (7.9%) hospital deaths.

21 alve replacement) (35, 0.9%), AVR (231, 6%), MVR (41, 1.06%), CABG + others (95, 2.46%), and others (

22 re were 46 patients identified (37 MVP and 9 MVR).

23 y in 370 patients undergoing VR (249 AVR, 93 MVR, 28 DVR).

24 19 patients with an EF < or = 30% received a MVR using an undersized nonflexible complete ring.

25 er AVR, 9.3% after AVR plus MVr, 10.5% after MVR, and 13.3% after AVR plus MVR (p < 0.001).

26 In this study, AI after MVR with en bloc adrenalectomy was frequent, even in pat

27 oint was incidence and relevance of AI after MVR.

28 l valve deterioration of bioprosthesis after MVR is higher than after AVR; after AVR, homografts and

29 th chronic MR before and 10 to 14 days after MVR.

30 The decline in EF after MVR for chronic MR is traditionally thought to be a cons

31 r AVR, and postoperative renal failure after MVR.

32 Significant limitation of function after MVR is uncommon.

33 Early mortality after MVR can be predicted on the basis of diagnosis and the s

34 survival was 95 +/- 1%; when mortality after MVR is included, 7-year survival was 83 +/- 6%.

35 thesis (66% vs. 79%, p = 0.02) but not after MVR.

36 after repair was better than survival after MVR for both PL-MVP (at 15 years, 41+/-5% versus 31+/-6%

37 All MVR and control patients underwent ablation under therap

38 P = .022) and MVR/SVP (66.2 +/- 12.4%, P = .017) groups than the MVR/N

39 was lower in the repair (1.8%, P = .046) and MVR/SVP (1.5%.

40 ion was BMVP in 64 patients, SMVP in 33, and MVR in 11.

41 Mortality after AVR and MVR is high at 10 to 15 years because of the associated

42 greater with bioprosthesis, both for AVR and MVR, and occurred at a much higher rate in those aged <6

43 Assessment of the trends in MV repair and MVR over time.

44 pect to age (P = .002) and in the repair and MVR/SVP groups with respect to NYHA functional class and

45 odds ratio, 0.27, P < .05) and of repair and MVR/SVP on overall mortality (hazard ratios, 0.43, P < .

46 The spatial features of release sites and MVR events are similarly tightened by buffering intracel

47 after either the sham procedure or anterior MVR; however, after posterior chordal-sparing MVR, theta

48 As MVR increases the likelihood of postsynaptic receptor sa

49 Operative mortality rates for AVR, MVR, combined CABG/AVR and combined CABG/ MVR were 4.00%

50 31, 2018, among patients who underwent AVR, MVR, or combined AVR-MVR at 3 medical centers and 4 regi

51 ents who underwent AVR, MVR, or combined AVR-MVR at 3 medical centers and 4 regional hospitals and co

52 ween 2.0 and 2.5.In the MVR and combined AVR-MVR groups, higher risks of composite thromboembolic eve

53 roup and 18 207 for the MVR and combined AVR-MVR groups.

54 alone, and 97 (10.8%) received combined AVR-MVR.

55 a mechanism by which a combination of basal MVR and low receptor saturation allow the presynaptic ac

56 These data can assist in choosing between MVR and alternative palliative strategies.

57 s how presynaptic integration of vesicles by MVR can increase the efficiency with which sensory infor

58 ortic valve replacement) (228, 5.9%), CABG + MVR (mitral valve replacement) (35, 0.9%), AVR (231, 6%)

59 R, MVR, combined CABG/AVR and combined CABG/ MVR were 4.00%, 6.04%, 6.80% and 13.29%, respectively.

60 ad CABG/mitral repair versus 56 who had CABG/MVR with preservation of the subvalvular apparatus.

61 ter CABG with mitral valve replacement (CABG/MVR).

62 Pairs of fusion events comprising MVR are also not perfectly synchronized, and the earlier

63 ngs define molecular mechanisms that control MVR and functional diversity of synaptic signaling.

64 t no valve replacement (n = 6), conventional MVR with chordal excision (n = 7), or chordal-sparing MV

65 After conventional MVR, baseline theta max fell by 66% to 81% in the antero

66 ular-ventricular integrity with conventional MVR reduced regional LV systolic torsion in the anterior

67 within an active zone is coordinated during MVR.

68 arious methods of chorda preservation during MVR to assess their impact on left ventricular systolic

69 We examined MVR at a ribbon synapse in a retinal slice preparation u

70 patients having smaller prostheses at first MVR (18.7+/-0.8 mm versus 22.4+/-3.6 mm, P=0.017).

71 (age <2 years and prosthesis <20 mm at first MVR) had an OR=46.3 compared with low-risk patients (age

72 or=2 years and prosthesis >or=20 mm at first MVR) over similar follow-up intervals.

73 sthesis survival was predicted only by first MVR age: odds ratio (OR) 7.7 (95% confidence interval [C

74 sis survival can be predicted based on first MVR age and prosthesis size.

75 had second MVR, prosthesis sizes were: first MVR 19+/-2 mm and second MVR 22+/-3 mm, and their body w

76 he 73 who did not have a second MVR on first-MVR demographic and perioperative variables.

77 Using first-MVR weight-matched controls, body weight increased simil

78 l LV torsional deformation acutely following MVR with and without chordal preservation.

79 Predictors of TE following MVR/DVR were raised mean platelet volume (4.0), raised f

80 0.001 for AVR and 44% vs. 4%, p = 0.0001 for MVR), and in patients > or =65 years after AVR, primary

81 years, 20+/-5% for repair versus 23+/-5% for MVR; P=0.4) or separately in PL-MVP (P=0.3) or AL-MVP (P

82 rial survival rates, 84% for AVR and 80% for MVR at 5 years, were not affected by VAI.

83 patients > or =60 to 65 years of age and for MVR in patients > or =65 to 70 years of age; in younger

84 Those who were candidates for MVR with en bloc adrenalectomy and had no preexisting ad

85 Unadjusted operative mortality for MVR only was 5.60% for blacks versus 6.18% for whites (O

86 A total of 7214 patients (44.4%) had MVR, and 9045 (55.6%) had MV repair.

87 nd June 2001, 1,195 consecutive patients had MVR with ring annuloplasty.

88 Here we investigate how MVR alters the transmission of sensory information compa

89 However, MVR should be considered for high-risk patients and thos

90 .2 ms produced larger reductions in MAP, HR, MVR and FVR compared with all low frequency and/or inter

91 uced similar sustained decreases in MAP, HR, MVR and FVR.

92 Initial MVR and younger age were associated with worse survival.

93 Complications after initial MVR included heart block requiring pacemaker (16%), endo

94 , which included 102 survivors after initial MVR, was analyzed.

95 ority of deaths occurred early after initial MVR, with little late attrition despite repeat MVR and c

96 an interval of 4.8+/-3.8 years after initial MVR.

97 Age at initial MVR was 1.9+/-1.4 years.

98 ality was 4.7% overall and 1.4% for isolated MVR (1.1% for minimally invasive surgery vs. 1.6% for co

99 as occurs in the auditory system of mammals, MVR increased information transfer whenever spike genera

100 using minisatellite variant repeat mapping (MVR) by PCR to gain insight into allelic diversity and t

101 ulation on MAP, heart rate (HR), mesenteric (MVR) and femoral (FVR) vascular resistance using low (5

102 l dual-blade device; (2) microvitreoretinal (MVR) blade; and (3) Trabectome.

103 icant morphological predictors necessitating MVR were found.

104 y (a) morphological predictors necessitating MVR, and (b) predictors of future reoperation within the

105 In 81.7% of MVR cases, no attempt at MV repair was made.

106 At last follow-up, 82.7% of MVR patients had their arrhythmia controlled (69.1% not

107 over an extended period, but the dynamics of MVR at ribbon synapses is unknown.

108 ch determines the spatiotemporal features of MVR events and is controlled, in part, by non-uniform ca

109 n the synaptic cleft, a result indicative of MVR, and suggests that MVR can be modified by long-term

110 h current solutions and clinical outcomes of MVR with mitral valve allograft.

111 strument may bring change in the paradigm of MVR by allowing repair with strong objective and quantit

112 We find that the presence of MVR and receptor saturation at this synapse alters the c

113 A large proportion of MVR was performed without an MV repair attempt, suggesti

114 These findings indicate that late results of MVR after minimally invasive surgery and after anterior

115 xible" patients required a repeat operation, MVR (1), and 2 patients required a transplant.

116 dels were developed: one for isolated AVR or MVR and one for CABG plus AVR or CABG plus MVR.

117 ications: prolonged ventilation after AVR or MVR, postoperative stay >14 days after AVR or MVR, reope

118 VR, postoperative stay >14 days after AVR or MVR, reoperation for bleeding after AVR, and postoperati

119 atients undergoing CABG combined with AVR or MVR.

120 ep sternal wound infection for either AVR or MVR.

121 en race and operative mortality after AVR or MVR.

122 redictor of operative mortality after AVR or MVR; however, black race was associated with an increase

123 of operative mortality after isolated AVR or MVR; however, there is evidence of an association betwee

124 f those patients who underwent either MVP or MVR between January 1, 1988, and December 31, 1998, for

125 ation rate was not different after repair or MVR overall (at 19 years, 20+/-5% for repair versus 23+/

126 free from failure of biventricular repair or MVR was 79% at 1 month and 55% at 5 years, with worse ou

127 scularization alone, mitral valve repair, or MVR.

128 Parallel to this organization, MVR events preferentially overlap with uni-vesicular rel

129 minisatellite variant repeat mapping by PCR (MVR-PCR), which determines the distribution of variant r

130 A minisatellite variant repeat PCR (MVR-PCR) system gives Y-specific DNA codes, with a virtu

131 r, 10.5% after MVR, and 13.3% after AVR plus MVR (p < 0.001).

132 ed with the lowest risk for PPM and AVR plus MVR with the highest risk.

133 r (MVr), 5.4% (n = 4,202) underwent AVR plus MVR, and 1.4% (n = 1,069) underwent AVR plus MVr.

134 on >30% were randomized to receive CABG plus MVR (34 patients) or CABG only (39 patients).

135 of peak oxygen consumption in the CABG plus MVR group compared with the CABG group (3.3 mL/kg/min ve

136 in the secondary end points in the CABG plus MVR group compared with the CABG group: left ventricular

137 ps: 3% and 9%, respectively in the CABG plus MVR group, versus 3% (P=1.00) and 5% (P=0.66), respectiv

138 stay duration were greater in the CABG plus MVR group.

139 r MVR and one for CABG plus AVR or CABG plus MVR.

140 t closure and recovery from anesthesia, post-MVR data were acquired.

141 eformation (theta max) did not fall from pre-MVR values in the baseline state after the sham procedur

142 fluoroscopic marker images were obtained pre-MVR in the baseline state and with inotropic stimulation

143 eplacement without subvalvular preservation (MVR/NoSVP).

144 d replacement with subvalvular preservation (MVR/SVP), and 318 had replacement without subvalvular pr

145 es-to-vertebral body signal intensity ratio (MVR) was calculated to compare modalities.

146 7%) received AVR alone, 329 (36.6%) received MVR alone, and 97 (10.8%) received combined AVR-MVR.

147 ents undergoing mitral valve reconstruction (MVR) with either a flexible or nonflexible complete ring

148 of such coordinated multivesicular release (MVR) for spike generation are not known.

149 ave a high degree of multivesicular release (MVR) in the absence of postsynaptic receptor saturation.

150 possibility is that multivesicular release (MVR) is determined by the instantaneous release probabil

151 Pronounced multivesicular release (MVR) occurs at the ribbon synapses of sensory neurones t

152 from univesicular to multivesicular release (MVR) when two Ca channels/AZ open at potentials above th

153 equency stimulation, multivesicular release (MVR), or asynchronous release can each activate NMDARs.

154 several vesicles, or multivesicular release (MVR), represents a simple mechanism to overcome the intr

155 ated by a process of multivesicular release (MVR).

156 ther it can increase multivesicular release (MVR).

157 vidual release site [multivesicular release (MVR)] and whether fusion of a single vesicle leads to re

158 This multi-vesicular release (MVR) occurs at most synapses, but its spatiotemporal pro

159 r multiple vesicles (multivesicular release, MVR) reflects variability in vesicle release probability

160 f multiple vesicles (multivesicular release; MVR) from single active zones occurs at some central syn

161 The role of mitral valve repair (MVR) during coronary artery bypass grafting (CABG) in pa

162 changes occurring after mitral valve repair (MVR).

163 R, with little late attrition despite repeat MVR and chronic anticoagulation.

164 nvestigated by Minisatellite Variant Repeat (MVR) analysis in a sample of >100 autochthonous individu

165 region using a minisatellite variant repeat (MVR)-PCR approach.

166 Using minisatellite variant repeat ("MVR") mapping, and compound haplotypes composed of the m

167 med in 46 patients (58%) and MV replacement (MVR) in 34.

168 placement (AVR) or mitral valve replacement (MVR) and from 43,463 patients undergoing CABG combined w

169 placement (AVR) or mitral valve replacement (MVR) at 13 VA medical centers were randomized to receive

170 atients undergoing mitral valve replacement (MVR) for chronic MR.

171 Mitral valve replacement (MVR) has a high mortality and morbidity.

172 al excision during mitral valve replacement (MVR) impairs left ventricular (LV) systolic function, bu

173 initial mechanical mitral valve replacement (MVR) in children <5 years of age are poorly defined.

174 s after prosthetic mitral valve replacement (MVR) in children aged <5 years are ill-defined and gener

175 nd to discuss when mitral valve replacement (MVR) may be favored over mitral valve repair.

176 ) and 482 isolated mitral valve replacement (MVR) operations with the St Jude Medical valve were stud

177 rall prevalence of mitral valve replacement (MVR) or MV repair at the time of cardiac surgery in the

178 Early attempts at mitral valve replacement (MVR) with mitral valve allograft were unsuccessful mainl

179 ave suggested that mitral valve replacement (MVR) with sparing of the subvalvular apparatus had compa

180 14,686) underwent mitral valve replacement (MVR), 10.5% (n = 8,219) underwent mitral valve repair (M

181 plasty (SMVP), and mitral valve replacement (MVR), although the optimal therapeutic strategy is uncle

182 patients requiring mitral valve replacement (MVR), mechanical prostheses (MPs) have been reported to

183 ; the alternative, mitral valve replacement (MVR), necessitates commitment to future valve replacemen

184 red after elective mitral valve replacement (MVR).

185 ts with mechanical mitral valve replacement (MVR).

186 placement (AVR) or mitral valve replacement (MVR).

187 terioration (SVD) (mitral valve replacement [MVR] > AVR) and, therefore, for replacement of the PHV.

188 ue to MVP (679 repairs and 238 replacements [MVRs]) was performed between 1980 and 1995.

189 d in the context of multivisceral resection (MVR).

190 Myocardial vascular resistance (MVR) increased with increasing triglyceride levels (r=0.

191 F-MLI synapses but, while some showed robust MVR with increased release probability, most were limite

192 ctors for having a second MVR, the 29 second MVR survivors were compared with the 73 who did not have

193 Twenty-nine survivors had undergone a second MVR at an interval of 4.8+/-3.8 years after initial MVR.

194 mpared with the 73 who did not have a second MVR on first-MVR demographic and perioperative variables

195 y for patients <2 years old who had a second MVR versus those who did not.

196 To identify risk factors for having a second MVR, the 29 second MVR survivors were compared with the

197 s sizes were: first MVR 19+/-2 mm and second MVR 22+/-3 mm, and their body weight increased from 7.4+

198 is an increment in prosthesis size at second MVR, suggesting continued annular growth.

199 Reasons for second MVR were prosthetic valve stenosis 24 (83%), thrombosis

200 comparable regardless of the need for second MVR.

201 For those who had second MVR, prosthesis sizes were: first MVR 19+/-2 mm and seco

202 dren <5 years old despite the risk of second MVR in the youngest patients in whom the smallest prosth

203 however, differed significantly, with second MVR patients having smaller prostheses at first MVR (18.

204 ng with repeat 7, characteristic "signature" MVR patterns emerge for each common allele.

205 Sham operation and anterior chordal-sparing MVR did not affect regional LV torsion; however, loss of

206 Posterior chordal-sparing MVR impaired torsion only after calcium administration.

207 , and the chordae tendineac, chordal-sparing MVR is popular.

208 ure or anterior or posterior chordal-sparing MVR procedure (P > or = .10).

209 chordal excision (n = 7), or chordal-sparing MVR with preservation of the posterior leaflet and reatt

210 VR; however, after posterior chordal-sparing MVR, theta max fell in the lateral, posterior, and poste

211 regurgitation who underwent either surgical MVR or MV repair between July 1, 2011, and June 30, 2022

212 ctive zones occurs at some central synapses, MVR is not thought to require coordination among release

213 ese results suggest that at PF-MLI synapses, MVR occurs under control conditions and is increased whe

214 s only slightly more commonly performed than MVR for isolated anterior leaflet pathologic status.

215 when Pr is elevated by facilitation and that MVR may be a phenomenon common to many synapses througho

216 Based on these data, it is clear that MVR mapping is a very useful tool for the analysis of zo

217 These findings establish that MVR and postsynaptic receptor saturation can influence t

218 We find that MVR can increase the number of spikes generated per vesi

219 Furthermore, we show that MVR may occur under baseline physiological conditions, a

220 We suggest that MVR occurs at SC-CA1 synapses when Pr is elevated by fac

221 result indicative of MVR, and suggests that MVR can be modified by long-term plasticity.

222 The MVR blade exhibited minimal removal of TM and obvious in

223 The MVR group was older (median [IQR] age, 70 [62-77] vs 67

224 records for the AVR group and 18 207 for the MVR and combined AVR-MVR groups.

225 s those with INRs between 2.0 and 2.5.In the MVR and combined AVR-MVR groups, higher risks of composi

226 he incidence of thromboembolic events in the MVR group with INRs in the range of 2.0 to 2.5 was not s

227 P = NS) groups than the MVR/NoSVP group (5.0%).

228 P (66.2 +/- 12.4%, P = .017) groups than the MVR/NoSVP group (63.5 +/- 3.4%).

229 of complete heart block was noted within the MVR group (37.5%).

230 d complete mitral annuloplasty ring as their MVR procedure.

231 Of patients who did not undergo MVR or repeat CBC, 8% were in New York Heart Association

232 In elderly patients undergoing MVR, actuarial analysis overestimates the 10-year risk o

233 outcomes in infants and patients undergoing MVR, but has improved in our more recent experience.

234 eedom from VD in elderly patients undergoing MVR.

235 nts were subclassified into those undergoing MVR with chordal preservation (group Ia) and those under

236 preservation (group Ia) and those undergoing MVR with chordal transection (group Ib).

237 04 patients > or = 70 years of age underwent MVR at our institution.

238 lack and 46,249 white patients who underwent MVR alone or AVR alone from 1999 through 2002.

239 nsory synapses overcome this problem and use MVR to encode signals of widely varying intensities.

240 Using MVR-PCR, 20 to 25 repeats at the 5' end of the VNTR can

241 three different retinal synapses to utilize MVR.

242 eservation of the subvalvular apparatus with MVR has a theoretical advantage in terms of ventricular

243 tion techniques are used in combination with MVR.

244 ue to MVP, mitral valve repair compared with MVR provides improved very long-term survival after surg

245 oved left ventricular function compared with MVR.

246 (IQR) annual hospital volume was lower with MVR vs MV repair (2.50 [1.50-5.00] vs 4.00 [2.00-7.00];

247 Patients with MVR had larger atria (p < 0.0001), lower left ventricula

248 he role of ablative therapy in patients with MVR is not yet established, with safety concerns and ver

249 cember 2008, we followed up 81 patients with MVR undergoing first-time AF ablation (compared with 162

250 ation is feasible and safe for patients with MVR.

251 7-year event-free survival (survival without MVR or repeat CBC) was 80 +/- 4%, 77 +/- 4%, 65 +/- 6%,